R&D News | pharmaphorum

News

Valo Health bags $2.7bn AI partnership with Novo Nordisk

Novo Nordisk has paid $60 million to partner Valo Health on a project that will apply the US start-up’s artificial intelligence-powered drug discovery engine to find new t

News

Novartis eyes first-line use of Lutathera after trial win

Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a ben

News

Seagen hails ‘practice-changing’ trial in bladder cancer

A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc

News

Machine learning puts virtual drug screening into high gear

Researchers in Finland have combined virtual drug screening with machine learning (ML) – carried out on supercomputers – to dramatically shorten the time taken to identify

News

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca

News

Travere weaker after Filspari fails confirmatory trial

Shares in Travere Therapeutics have lost more than 40% of their value after the company said that a trial designed to confirm the benefits of its recently approved Filspar

Valo Health bags $2.7bn AI partnership with Novo Nordisk

Novartis eyes first-line use of Lutathera after trial win

Seagen hails ‘practice-changing’ trial in bladder cancer

Machine learning puts virtual drug screening into high gear

AZ, Daiichi Sankyo cue up TROP2 drug filing in breast cancer

Travere weaker after Filspari fails confirmatory trial

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks